ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
J

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary Analysis of the CAPTIVATE Study

By ecancer FEATURING John Allan
By ecancer FEATURING John Allan
22 views
September 6, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

19:39
Pfizer Hematology

Making the First Chance Count: Manuel

Feat. A. Ip

Featured Video

19:51
AstraZeneca Oncology

Management Strategies for Fatigue and Asthenia in First-line Mainten…

Feat. D. Czel, C. Arn
Leukemia
07:33

Epitope Editing Enables Targeted Immunotherapy of AML

ecancer

G. Casirati

22 views
04:14

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

ecancer

J. Brown

506 views
04:55

First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib…

ecancer

J. Byrd

405 views
04:36

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

26 views
10:41

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

ecancer

J. Allan

22 views
05:12

EHA 2021 Update on Venetoclax + Obinutuzumab in Untreated CLL: 4-yea…

ecancer

O. Al-Sawaf

16 views
07:02

EHA 2021 Primary Analysis From the OPTIC Trial on CP-CML: A Dose-Ran…

ecancer

J. Cortés

27 views
07:36

EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CL…

ecancer

A. Kater

12 views
05:52

EHA 2021 Update on Blinatumomab for MRD-Positive B-Cell ALL

ecancer

N. Short

17 views
05:42

EHA 2021 Update on Blinatumomab + Ponatinib for Ph+ ALL: Interim Res…

ecancer

N. Short

127 views
09:22

EHA 2021 Update on KTE-X19, an Anti-CD19 CAR T-Cell Therapy for R/R …

ecancer

B. Shah

68 views
05:28

2020 ASH Update on IDH 1/2-Mutated AML: Does Ven+Aza vs. Aza Mono Im…

ecancer

H. Kantarjian

14 views